p.37 抽出テキスト

リスク・患者評価

3

Nephropathy After Coronary Angiography:A Comprehensive Meta—Analysis and Systematic Review of 125 Randomized Controlled Trials. Angiology 2016;68:389—413.〔I〕16) Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF:The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast—induced nephropathy. Int Urol Nephrol 2008;40:749—755.〔IVa〕17) Bainey KR, Rahim S, Etherington K, Rokoss ML, Natarajan MK, Velianou JL, Brons S, Mehta SR, CAPTAIN Investigators:Effects of withdrawing vs continuing renin—angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization:Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization(CAPTAIN)trial. American Heart Journal 2015;170:110—116.〔II〕18) Wolak T, Aliev E, Rogachev B, Baumfeld Y, Cafri C, Abu—Shakra M, and Novack, V:Renal safety and angiotensinII blockade medications in patients undergoing non—emergent coronary angiography:a randomized controlled study. The Israel Medical Association Journal:IMAJ 2013;15:682—687.〔II〕19) Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH:Contrast Material—induced Nephrotoxicity and Intravenous Low—Osmolality Iodinated Contrast Material. Radiology 2013;267:94—105.〔IVa〕20) Shemirani H, Pourrmoghaddas M:A randomized trial of saline hydration to prevent contrast—induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention. Saudi J Kidney Dis Transpl 2012;23:280—285.〔II〕21) Solomon R, Wener C, Mann D, D’Elia J, Silva P:Effects of saline, mannitol, and furosemide to prevent acute decrease in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416—1420.〔II〕22) Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas—Malo M, Taqylor DA, Teo KK:Forced euvolemic diuretic with mannitol and furosecemide for prevention of cantrast—induced nephropathy in patients with CKD undergoing coronary angiography:a randomized controlled trial. Am J Kidney Dis 2009;54:602—609.〔II〕23) Neyra JA, Shah S, Mooney R, Jacobsen G, Yee J, Novak JE:Contrast—induced acute kidney injury following coronary angiography:a cohort study of hospitalized patients with or without chronic kidney disease. Nephrol Dial Transplant 2013;28:1463—1471.〔IVa〕24) Putzu A, Boscolo Berto M, Belletti A, Pasotti E, Cassina T, Moccetti T, Pedrazzini G:Prevention of Contrast—Induced Acute Kidney Injury by Furosemide With Matched Hydration in Patients Undergoing Interventional Procedures: A Systematic Review and Meta—Analysis of Randomized Trials. JACC Cardiovascular Interventions 2017;10:355— 363.〔I〕25) Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM:Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure:A population—based, nested case—control analysis. Am J Epidemiol 2006;164(9):881—889.〔IVb〕26) The Society for Cardiovascular Angiography and Interventions(SCAI):Prevention of contrast induced nephropathy:recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007;69:135—140. 27) Barrett BJ, Parfrey PS:Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354:379—386.〔V〕28) Jain V, Sharma D, Prabhakar H, Dash HH:Metformin—associated lactic acidosis following contrast media—induced nephrotoxicity. Eur J Anaesthesiol 2008;25:166—167.〔V〕29) Safadi R, Dranitzki—Elhalel M, Popovtzer Ben—Yehuda A:Metformin—induced lactic acidosis associated with acute renal failure. Am J Nephrol 1996;16:520—522.〔V〕30) Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB:Metformin and lactic acidosis:cause or coincidence? A review of case reports. J Intern Med 2004;255:179—187.〔V〕31) McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD:Metformin and contrast media— a dangerous combination? Clin Radiol 1999;54:29—33.〔V〕32) Rasuli P, Hammond DI:Metformin and contrast media:where is the conflict? Can Assoc Radiol J 1998;49:161— 166.〔VI〕33) Zeller M, Labalette—Bart M, Juliard JM, Potier L, Feldman LJ, Steg PG, Cottin Y, Roussel R:Metformin and contrast— induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction:Amulticenter study. Int J Cardiol 2016;220:137—142.〔IVa〕34) Goergen SK, Rumbold G, Compton G, Harris C:Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 2010; 254:261—269.〔I〕35) Khurana R, Malik IS:Metformin:safety in cardiac patients. Heart 2010;96:99—102.〔VI〕36) Holstein A, Stumvoll M:Contraindications can damage your health—is metformin a case in point? Diabetologia 2005; 48:2454—2459.〔VI〕37) Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW,

Leon MB, Mehran R:Contrast—induced nephropathy after percutaneous coronary interventions in relation to